In a new job - February 21, 2018
New General Manager Nordics at Bristol Myers Squibb
Iddo Leshem commenced his role as General Manager, Bristol Myers Squibb (BMS) Nordics in January 2018. The Nordics’ business has over 200 employees and Iddo will be based at BMS’s Swedish office in Solna, Stockholm. “Our mission is to translate cutting edge science into innovative medicines that extend and improve lives of patients combating serious […]
Acquisition - July 10, 2016
BMS acquires Cormorant Pharmaceuticals
Bristol-Myers Squibb has acquired all of the outstanding capital stock of Cormorant, a private, Stockholm, Sweden-based pharmaceutical company focused on the development of therapies for cancer and rare diseases. The acquisition gives Bristol-Myers Squibb full rights to Cormorant’s HuMax-IL8 antibody program and the lead candidate HuMax-IL8, a Phase 1/2 monoclonal antibody targeted against interleukin-8 (IL-8) […]
Regulatory compliance - June 2, 2015
BMS Sues Exec Who Goes to AZ
Bristol-Myers Squibb has filed a lawsuit against a former executive for accepting a job with AstraZeneca, alleging he violated a non-compete agreement in the process, according to court documents. The executive, David Berman, who worked for Bristol-Myers for a decade, most recently was the vice president of the company’s immuno-oncology exploratory development team. He was promoted […]
Acquisition - March 25, 2015
Novo Sells Autoimmune Program
Novo Nordisk has sold one of its early-stage autoimmune research programs to Bristol-Myers Squibb for an undisclosed amount. As part of the agreement, Bristol-Myers obtains the exclusive rights to a discovery-stage biologics program that targets the innate immune system, which is the body’s first line of defense against infection. Novo’s program was striving to treat […]
Acquisition - February 3, 2014
AstraZeneca completes acquisition of BMS diabetes share
AstraZeneca has completed the acquisition of the entirety of Bristol-Myers Squibb’s interest in the companies’ diabetes alliance. In December last year, the news about the acquisition were announced and on February 1 2014 the deal was completed. According to the agreement, AstraZeneca gets ownership of the intellectual property and global rights for the development, manufacture and […]
Agreement - December 20, 2013
AstraZeneca buys Bristol-Myers Squibb share of global diabetes alliance assets
According to the agreement AstraZeneca will acquire the entirety of Bristol-Myers Squibb’s interests in the companies’ diabetes alliance for an initial consideration of $2.7 billion on completion and up to $1.4 billion in regulatory, launch and sales-related payments. Furthermore, AstraZeneca has agreed to pay various sales-related royalty payments up until 2025. In addition, AstraZeneca states […]
